Skip to main content
Howard Trachtman, MD, Pediatric Nephrology, New York, NY

HowardTrachtmanMD

Pediatric Nephrology New York, NY

Professor of Pediatrics, NYU School of Medicine

Dr. Trachtman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Trachtman's full profile

Already have an account?

Education & Training

  • Jacobi Medical Center
    Jacobi Medical CenterResidency, Pediatrics, 1980 - 1983
  • Tufts Medical Center
    Tufts Medical CenterResidency, Pediatrics, 1978 - 1980
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1978

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1992 - Present
  • NY State Medical License
    NY State Medical License 1981 - 2022
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Nephrology

Awards, Honors, & Recognition

  • New York Magazine: Top Doctors Castle Connolly, 2002-2003, 2005-2019
  • Top Doctors: New York Metro Area Castle Connolly, 2002-2014
  • Newsday - Top Doctors on Long Island Castle Connolly, 2008, 2010-2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Does What Goes Around Always Come Around?  
    Howard Trachtman, MD, Journal of the American Society of Nephrology
  • DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS  
    Howard Trachtman, Peter Nelson, Abanti Chaudhuri, Jai Radhakrishnan, Olga Zhdanova, Debbie S Gipson, Tarak Srivastava, Kenneth Lieberman, Vimal Kumar Derebail, Jonatha..., Journal of the American Society of Nephrology

Press Mentions

  • Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
    Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of NephrologyOctober 25th, 2018
  • Experimental Drug More Effective in Treating Rare Kidney Disease
    Experimental Drug More Effective in Treating Rare Kidney DiseaseOctober 26th, 2018
  • Novel Drug Shows Promise for FSGS
    Novel Drug Shows Promise for FSGSNovember 28th, 2016
  • Join now to see all

Professional Memberships